NOVO-NORDISK A/S-SPONS ADR (NVO)

US6701002056 - ADR

91.3  +0.01 (+0.01%)

After market: 91.53 +0.23 (+0.25%)

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (9/22/2023, 7:16:28 PM)

After market: 91.53 +0.23 (+0.25%)

91.3

+0.01 (+0.01%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)11-02 2023-11-02/bmo
Ins OwnersN/A
Inst Owners6.5%
Market Cap408.47B
Shares4.47B
PE21.33
Fwd PE14.93
Dividend Yield1.1%
Analysts70.63
IPO05-17 1974-05-17
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NVO Daily chart

Company Profile

Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO-NORDISK A/S-SPONS ADR

Novo Alle 1

Bagsvaerd 2880

P: 4544448888.0

CEO: Lars Fruergaard Jorgensen

Employees: 59337

Website: https://www.novonordisk.com/

NVO News

News Imagea day ago - Investor's Business DailyStock Market Falls Into Correction On Hawkish Fed: Weekly Review

Treasury yields surged to long-term highs, while leading stocks buckled.

News Imagea day ago - The Motley FoolWhere Will Novo Nordisk Stock Be in 5 Years?

Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come.

News Imagea day ago - ChartmillDon't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.

In the world of growth stocks, NYSE:NVO shines as a value proposition.

News Image2 days ago - The Motley FoolWhy Novo Nordisk Stock Was Tumbling on Thursday

A downbeat analyst take resonated with investors.

News Image2 days ago - Investor's Business DailyFDA Inspection Turns Up 'Objectionable' Bacteria In Key Novo Nordisk Plant

The company says it has since corrected the issues found in the FDA inspection.

News Image3 days ago - The Motley FoolWhy Novo Nordisk Stock Edged Higher Today

The good news outweighed the bad for the hot drug developer on Hump Day.

NVO Twits

Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example